American Journal of Ophthalmology
Volume 150, Issue 3 , Pages 310-314 , September 2010

Efficacy of Ranibizumab in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion: Results From the Sham-Controlled ROCC Study

  • Bettina Kinge

      Affiliations

    • Retinaklinikken Aleris, Oslo, Norway
    • Corresponding Author InformationInquiries to Bettina Kinge, Retinaklinikken Aleris, Fredrik Stangsgt 11-13, 0264 Oslo, Norway
    • ,
  • Per Bjørn Stordahl

      Affiliations

    • Retinaklinikken Aleris, Oslo, Norway
    • ,
  • Vegard Forsaa

      Affiliations

    • Department of Ophthalmology, University Hospital, Stavanger, Norway
    • ,
  • Kristian Fossen

      Affiliations

    • Department of Ophthalmology, University Hospital, Tromsø, Norway
    • ,
  • Marta Haugstad

      Affiliations

    • Department of Ophthalmology, Oslo University Hospital, Oslo, Norway
    • ,
  • Ole Harald Helgesen

      Affiliations

    • Department of Ophthalmology, University Hospital, Tromsø, Norway
    • ,
  • Johan Seland

      Affiliations

    • Department of Ophthalmology, University Hospital, Stavanger, Norway
    • ,
  • Ingar Stene-Johansen

      Affiliations

    • Department of Ophthalmology, Oslo University Hospital, Oslo, Norway

,Accepted 30 March 2010.

References 

  1. Arvas S, Ocakoglu O, Ozkan S. The capillary blood flow in ischaemic type central retinal vein occlusion: the effect of laser photocoagulation. Acta Ophthalmol Scand. 2002;80(5):490–494
  2. The Central Vein Occlusion Study Group N Report. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. Ophthalmology. 1995;102(10):1434–1444
  3. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138(5):740–743
  4. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol. 2004;137(4):758–760
  5. Cekic O, Chang S, Tseng JJ, et al. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol. 2005;139(6):993–998
  6. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology. 1983;90(5):458–474
  7. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115(4):486–491
  8. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–1487
  9. Boyd SR, Zachary I, Chakvarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002;120(12):1644–1650
  10. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103(11):1820–1828
  11. Itturalde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26(3):279–284
  12. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO Study. Retina. 2007;27(2):141–149
  13. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol. 2007;144(6):864–871
  14. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142(6):961–969
  15. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113(10):1706–1712
  16. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147(2):298–306
  17. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology. 2008;115(10):e47–e54
  18. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009;93(4):452–456
  19. von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol. 2010;88(2):263–266

PII: S0002-9394(10)00253-9

doi: 10.1016/j.ajo.2010.03.028

American Journal of Ophthalmology
Volume 150, Issue 3 , Pages 310-314 , September 2010

Article Tools

* Image Usage & Resolution